Anand Rathi Projects Jubilant Ingrevias FY27 Earnings Upswing as CDMO and Specialty Segments Strengthen

Anand Rathi Research has returned to Jubilant Ingrevia with a firm “Buy” recommendation, raising its target price to...

Read story →